The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum.
Morten Mau-Soerensen
Research Funding - GlaxoSmithKline
Olfred Hansen
No relevant relationships to disclose
Bente Holm
No relevant relationships to disclose
Christa Haugaard Nyhus
No relevant relationships to disclose
Tine McCulloch
No relevant relationships to disclose
Henrik Anker Nielsen
No relevant relationships to disclose
Kim Wedervang
No relevant relationships to disclose
Carsten Rytter
No relevant relationships to disclose
Nina Jeppesen
No relevant relationships to disclose
Seppo Langer
No relevant relationships to disclose